LNG-IUD + Semaglutide for Endometrial Cancer

(SWIFT Trial)

This trial tests a new treatment for women with early-stage endometrial cancer or atypical hyperplasia who wish to preserve fertility. The treatment combines a hormonal IUD (LNG-IUD), semaglutide, and a weight loss program to assess its effectiveness. The trial aims to determine the number of participants achieving a complete response, the duration of this response, and the impact on weight and quality of life. Suitable candidates have a confirmed diagnosis, desire to preserve fertility, and meet specific weight criteria or have related health issues like diabetes or sleep apnea. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group.

Earlier studies have examined the safety of both the LNG-IUD and semaglutide, yielding encouraging results. The LNG-IUD effectively provides birth control and offers additional health benefits, such as reducing heavy periods. Some research even shows it can completely reverse certain conditions, indicating its efficacy without causing serious harm.

Semaglutide has undergone extensive study and is considered safe for weight management and improving overall health. Large studies have shown it does not increase cancer risk, which is reassuring. In fact, semaglutide is associated with a lower risk of some cancers and fewer hospital visits, making it a well-tolerated choice for many people.

Researchers are excited about this treatment combination for endometrial cancer because it offers a novel, fertility-sparing approach. Unlike traditional treatments like surgery or hormone therapy alone, this approach combines a levonorgestrel-releasing intrauterine device (LNG-IUD) with semaglutide, a medication typically used for weight management and diabetes, along with a structured weight loss program. This combination aims not only to treat the cancer but also to improve overall health and preserve fertility, which is a significant concern for many patients. Additionally, semaglutide introduces a new mechanism of action by helping with weight loss, which can further support cancer treatment and potentially improve outcomes.

Research has shown that the LNG-IUD, a hormonal device placed in the uterus, effectively treats endometrial hyperplasia. One study found a 100% success rate after six months. Semaglutide, a medication known for aiding weight loss and improving metabolic health, may also benefit conditions affecting the uterine lining. In this trial, participants will receive a combination of the LNG-IUD and semaglutide, along with a structured weight loss program, to explore their combined effects on early-stage endometrial cancer while preserving fertility. Initial findings suggest that the LNG-IUD can reverse abnormal cell growth in the uterine lining, and semaglutide might enhance these effects by improving overall health. This combination could increase the chances of completely eliminating the disease after treatment.⁶⁷⁸⁹¹⁰